Marketed and experimental medicines for the treatment of Benigun Prostatic Hyperplasia and Prostate Cancer in the UK

Company	Product name /number	Product type	Phase of development					Status and comment (October 2000)
			PC	I	II	III	L
Abbott Laboratories	Terazosin	Selective alpha-1 blocker
	ABT-980	Selective alpha-1 blocker						Treatment for BPH
	ABT-627	Endothelin antagonist						Possible treatment for prostate cancer
Asta Medica	Tetrasodium forfesterol	Oesrogen prodrug
	Cetrorelix	LHRH antagonist
AstraZeneca	Bicalutamide	Non-steroidal anti-androgen
	Goserelin	LHRH antagonist
	ZD 1839 (Iressa)	Tyrosine Kinase inhibitor						Under assessment in hormone-resistant cancer
	ZD6126	Vascular Targeting agent						First clinical trial expected in 2000
	ZD6474	Anti-angiogenic						First clinical trial expected in 2000
Aventis	Taxotere	Microtubule inhibitor						Already authorised for some advanced forms of breast and lung cancer
Bristol-Myers Squibb	Paclitaxel	Microtuble inhibitor						Reports of useful activity in prostate cancer
	Megesterol acetate	Steroidle anti-androgen
Genta Pharma	G3139	Anti-sense DNA blocker						Binds to oncogene, bcl-2 expressed in prostae cancer
Glaxo Wellcome	GI 198745	5-alpha reductase (Type 1 and 2) inhibitor						For BPH. Ihibits both Type 1 and Type 2 5-alpha-reductase
Immunex	Mitroxantrone	Cyotoxic						In combination with G3139
Ipsen	Triptorekin SR	Slow release LHRH agonist
Malgainin Pharma	Squalamine	Anti-angiogenic						Natural product from the dogfish shark
Merck Sharp & Dohme	Finasteride	5-alpha reductase (Type2) inhibitor
MGI Pharma	Irofulven (MGI-114)	DNA synthesis inhibitor
Novartis	Xoledronate (CGP-42446)	Third gegeration bisphosphonate						Possible introduction in the UK in mid-2001
Nycomed Amersham	Iodine125 'seeds'	Implanted radiotherapeutic
	Metastron	Radioisotope of strontium						For relief of bone pain in prostate cancer
OXIGENE/Cancer Research Campaign	Combretastatin A4	Anti-angiogenic						Blocker of tumour blood supply
Pfizer	Doxazosin	Alpha-1 blocker
	Prazosin	Alpha-1 blocker
	Quinazoline and quiazoline derivatives	Selective blockers of alpha-1 sub-types
Pharmacia & Upjohn	Estramustine Phosphate	Estrogenic alkylating agent
	Medroxy-progesterone acetate	Progestogen
Pierre Fabre	Vinorelbine	Vinca alkaloid
	Lipidosterol extract	5-alpha reductase (Types 1 and 2) inhibitor						Available in most EU countries, but not in the UK
Sanofi-Synthelabo	Alfuzosin-xl	Uroselective alpha-1 blocker
	Abarelix	Slow release LHRH antagonist
Schering Health Care	Cyproterone acetate	Steroidal anti-androgen
Schering Plough	Flutamide	Non-steroidal anti-androgen
Shwartz Pharma	CEP-701	Tyrosine kinase						With Cephalon for markets outside the USA
Shire	Buserelin	LHRH agonist
SmithKline Beecham	Indoramin	Selective alpha-1 blocker
Wyeth	Leuprorelin SR	LHRH agonist						One and 3 monthly depots available.Not available for prostate cancer, but some encouraging early trial results
	Mitoxantrone	Cytotoxic
Yamanouchi	Tamsulosin	Selective alpha-1 blocker						Incooperation with Glaxo Wellcome